Pharma BD Deal Intelligence
Merck's $1.85B all-cash acquisition of Pandion Therapeutics landed a Treg-selective IL-2 mutein, MK-6194, that reached Phase 2 in vitiligo and lupus before Merck discontinued it in July 2025 after the drug "did not confer clinical benefit." A bust: the deal's core clinical rationale evaporated with nothing to show for it.
Merck acquired Pandion Therapeutics for $1.85B for autoimmune disease treatment.
NCT06113328 — Phase 2a MK-6194 in non-segmental vitiligo, sponsor Merck Sharp & Dohme, 169 enrolled. Overall status: Terminated (business reasons). Primary…
Merck to acquire Pandion Therapeutics for $60 per share approximately $1.85 billion gaining TALON technology.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck (NYSE: MRK) acquired Pandion Therapeutics in an all-cash tender offer of $60.00 per share, ~$1.85 billion, announced February 25, 2021 and completed April 1, 2021. The deal brought Pandion's TALON (bispecific tethered effector) platform and its lead asset PT101 (renamed MK-6194), an engineered IL-2 mutein designed to selectively expand regulatory T cells for autoimmune disease. Under Merck, MK-6194 advanced into Phase 2, including a Phase 2a study in non-segmental vitiligo (NCT06113328) and exploratory work in systemic lupus erythematosus and ulcerative colitis. In July 2025 Merck discontinued MK-6194 after a review of primary results from trial MK-6194-007 and exploratory Phase 1b data showed the candidate "did not confer clinical benefit" (Merck spokesperson); the move came amid a broader ~$3B cost-cutting program. The vitiligo study was terminated (status: Terminated, business reasons; primary completion March 2025). Phase 1 PK/PD data (ImmunoHorizons, March 2025) confirmed dose-dependent, Treg-selective expansion, but efficacy did not translate. The outcome leaves the $1.85B acquisition without a clinical asset to show for its core rationale.
24M US cases/yr · $80.0B Global Autoimmune Market
Merck acquired Pandion for $1.85B for IL-2 mutein (PT101/MK-6194) Treg activator. Discontinued after Phase 2 showed no clinical benefit.
$1.85B write-off. IL-2 Treg space remains active (Lilly/Nektar, Roche) but clinical translation challenging.
204K US cases/yr · $3.4B US SLE market (2024) · ~90% Female prevalence
Systemic lupus erythematosus is a chronic autoimmune disease where the immune system attacks healthy tissue. Current treatments include corticosteroids, antimalarials, immunosuppressants, and belimumab. Selective Treg expansion via engineered IL-2 represents a novel mechanistic approach.
Pandion's PT101 (MK-6194) was being developed for multiple autoimmune indications including SLE, leveraging selective Treg activation to restore immune tolerance. The program was divested by Merck.
Merck completed $1.85B acquisition of Pandion Therapeutics, gaining engineered IL-2 muteins to selectively expand regulatory T cells for autoimmune diseases.
Merck advanced Pandion-derived Treg programs targeting IBD and autoimmune conditions with selective IL-2 activation approach.
Merck discontinued MK-6194 (lead Pandion asset) in July 2025 after trial MK-6194-007 and Phase 1b exploratory data showed no clinical benefit. Phase 2a vitiligo study NCT06113328 terminated. Core rationale of the $1.85B acquisition written off.
Treg-selective IL-2 still in development with no pivotal readouts. $1.85B remains speculative bet on novel immunology mechanism.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Pandion Therapeutics (this deal) | 2021 | $1.9B | 52 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2021 deals · Merck & Co. Inc. deals · Immunology deals